金城医药
(300233)
| 流通市值：49.25亿 | | | 总市值：50.79亿 |
| 流通股本：3.72亿 | | | 总股本：3.84亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,447,244,579.85 | 750,421,565.86 | 2,736,927,222.73 | 1,932,025,566.29 |
| 营业收入 | 1,447,244,579.85 | 750,421,565.86 | 2,736,927,222.73 | 1,932,025,566.29 |
| 二、营业总成本 | 1,317,835,512.27 | 675,692,157.8 | 2,629,657,047.77 | 1,891,362,105.7 |
| 营业成本 | 935,464,712.25 | 490,685,836.34 | 1,750,628,414.68 | 1,232,102,059.3 |
| 税金及附加 | 21,526,549.01 | 11,243,099.24 | 37,370,131.69 | 27,146,432.33 |
| 销售费用 | 117,498,285.53 | 53,093,892.41 | 308,692,191.41 | 240,612,485 |
| 管理费用 | 156,283,129.54 | 78,517,198.92 | 338,976,571.38 | 276,986,607.8 |
| 研发费用 | 78,297,469.97 | 37,918,408.58 | 188,462,024.17 | 111,830,849.91 |
| 财务费用 | 8,765,365.97 | 4,233,722.31 | 5,527,714.44 | 2,683,671.36 |
| 其中:利息费用 | 4,016,901.67 | 1,990,244.33 | 10,811,664.9 | 8,524,621.28 |
| 其中:利息收入 | 2,080,282.75 | 999,017.42 | 6,579,030.8 | 5,410,746.72 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -117,247.22 | -149,091.12 | -86,057.68 | -108,724.65 |
| 加:投资收益 | 23,875,917.53 | 859,653.08 | 2,787,697.93 | 961,429.24 |
| 资产处置收益 | 47,831,639.42 | 201,732.88 | 2,948,972.26 | -388,847.35 |
| 资产减值损失(新) | -40,725,721.44 | -4,944,348.92 | -55,662,378.95 | -17,860,007.5 |
| 信用减值损失(新) | 338,944.05 | -869,904.83 | 3,127,582.17 | 12,203,448.98 |
| 其他收益 | 14,168,175.89 | 7,172,893.22 | 23,830,521.61 | 17,414,312.81 |
| 四、营业利润 | 174,780,775.81 | 77,000,342.37 | 84,216,512.3 | 52,885,072.12 |
| 加:营业外收入 | 548,507.42 | 308,794.41 | 1,502,949.13 | 247,970.1 |
| 减:营业外支出 | 1,949,626.97 | 1,152,662.59 | 7,698,240.26 | 2,555,207.11 |
| 五、利润总额 | 173,379,656.26 | 76,156,474.19 | 78,021,221.17 | 50,577,835.11 |
| 减:所得税费用 | 31,887,093.73 | 17,146,234.85 | 35,747,460.94 | 16,979,757.39 |
| 六、净利润 | 141,492,562.53 | 59,010,239.34 | 42,273,760.23 | 33,598,077.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 141,492,562.53 | 59,010,239.34 | 42,273,760.23 | 33,598,077.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 138,873,498.2 | 57,794,502.76 | 44,186,259.69 | 31,577,078.65 |
| 少数股东损益 | 2,619,064.33 | 1,215,736.58 | -1,912,499.46 | 2,020,999.07 |
| 扣除非经常损益后的净利润 | 66,199,860.27 | 53,315,937.43 | 30,163,155.91 | 21,909,810.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.37 | 0.15 | 0.12 | 0.08 |
| (二)稀释每股收益 | 0.37 | 0.15 | 0.12 | 0.08 |
| 八、其他综合收益 | -750,000 | - | -1,702,679.15 | -33,584.91 |
| 归属于母公司股东的其他综合收益 | -750,000 | - | -1,702,679.15 | -33,584.91 |
| 九、综合收益总额 | 140,742,562.53 | 59,010,239.34 | 40,571,081.08 | 33,564,492.81 |
| 归属于母公司股东的综合收益总额 | 138,123,498.2 | 57,794,502.76 | 42,483,580.54 | 31,543,493.74 |
| 归属于少数股东的综合收益总额 | 2,619,064.33 | 1,215,736.58 | -1,912,499.46 | 2,020,999.07 |
| 公告日期 | 2026-08-21 | 2026-04-24 | 2026-03-27 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |